$HIMS
Hims & Hers Health, Inc.

2019 Q2 Form 10-Q Financial Statement

#000119312519234151 Filed on August 29, 2019

View on sec.gov

Income Statement

Concept 2019 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses
YoY Change
Operating Profit -$16.61K
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$16.61K
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $500.0K
YoY Change
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets $536.3K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $21.98K
YoY Change
Accrued Expenses $449.1K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $100.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $527.9K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $527.9K
Total Long-Term Liabilities $0.00
Total Liabilities $500.0K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$16.61K
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $0.00
YoY Change
Total Liabilities & Shareholders Equity $536.3K
YoY Change

Cashflow Statement

Concept 2019 Q2
OPERATING ACTIVITIES
Net Income -$16.61K
YoY Change
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities 0.000
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
Oaktree Acquisition Corp.
dei Entity Central Index Key
EntityCentralIndexKey
0001773751
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2019Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
536322
CY2019Q2 us-gaap Assets
Assets
536322
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
449066
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
21979
CY2019Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
56883
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
527928
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24497
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16606
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
8394
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
536322
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16606
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-16606
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5031250
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
494968750
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
0
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
0
CY2019Q2 us-gaap Shares Outstanding
SharesOutstanding
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
0
CY2019Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
12214
CY2019Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4392
CY2019Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0
CY2019Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
0
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2019Q2 oacu Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
-436852
CY2019Q2 oacu Deferred Offering Costs Included In Accounts Payablemember
DeferredOfferingCostsIncludedInAccountsPayablemember
-17587
CY2019Q2 oacu Deferred Offering Costs Advanced By Related Party
DeferredOfferingCostsAdvancedByRelatedParty
-56883
CY2019Q2 oacu Deferred Offering Costs Paid By Sponsor In Exchange For Issuance Of Classb Ordinary Shares
DeferredOfferingCostsPaidBySponsorInExchangeForIssuanceOfClassbOrdinaryShares
-25000
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2019Q2 oacu Advances From Related Party Agreed Amount
AdvancesFromRelatedPartyAgreedAmount
300000000
CY2019Q3 oacu Common Stock Subject To Forfeiture
CommonStockSubjectToForfeiture
656250
CY2019Q2 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div><div style="text-indent: 3%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q2 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div><div style="text-indent: 3%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the unaudited condensed financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the&#160;unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment.&#160;It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future conforming events.&#160;Accordingly, the actual results could differ from those estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q2 oacu Deferred Offering Costs Associated With The Initial Public Offering
DeferredOfferingCostsAssociatedWithTheInitialPublicOffering
<div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Deferred offering Costs Associated with the Initial Public Offering </div></div></div><div style="text-indent: 3%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Deferred offering costs consist of legal, accounting, underwriting fees and other costs incurred through the date of the financial statements that are directly related to the Initial Public Offering, and were charged to shareholders&#8217; equity upon the completion of the Initial Public Offering on July&#160;22, 2019. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2019Q2 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
25000
CY2019Q2 oacu Percentage Of Founder Shares On Outstanding Shares
PercentageOfFounderSharesOnOutstandingShares
0.20
us-gaap Conversion Of Stock Description
ConversionOfStockDescription
20%&#160;of the sum of (i)&#160;the total number of Class&#160;A ordinary shares issued and outstanding upon completion of the Initial Public Offering, plus (ii)&#160;the total number of Class&#160;A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class&#160;A ordinary shares or equity-linked securities exercisable for or convertible into Class&#160;A ordinary shares issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor upon conversion of Working Capital Loans.
oacu Common Stock Shares Resale Or Transfer Share Price Threshold
CommonStockSharesResaleOrTransferSharePriceThreshold
12.00

Files In Submission

Name View Source Status
0001193125-19-234151-index-headers.html Edgar Link pending
0001193125-19-234151-index.html Edgar Link pending
0001193125-19-234151.txt Edgar Link pending
0001193125-19-234151-xbrl.zip Edgar Link pending
d782478d10q.htm Edgar Link pending
d782478dex311.htm Edgar Link pending
d782478dex312.htm Edgar Link pending
d782478dex321.htm Edgar Link pending
d782478dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
oacu-20190630.xml Edgar Link completed
oacu-20190630.xsd Edgar Link pending
oacu-20190630_cal.xml Edgar Link unprocessable
oacu-20190630_def.xml Edgar Link unprocessable
oacu-20190630_lab.xml Edgar Link unprocessable
oacu-20190630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending